Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: BID .1275 x ask .1280

Thanks for clarifying. I'll try to go back and relisten. It seems that PDS working capital was approaching levels that would not only be negative from a cash flow perspective, but if the legal battles and associated costs continue, might ultimately go negative on the balance sheet if the licensing is low as you expect. I don't remember specifically what the balance sheet showed, but will look into it more when I have time. If it gets to that point, PTSC will HAVE to fund PDS by agreement I believe, so while I'd hate to see it ever get there, it would be interesting, as that would force PTSC's hand to show what it really thinks of the MMP's future.

Share
New Message
Please login to post a reply